GlassScriptPhysician profile
Treacy Williams
NPI 1477184299
$2,599.58
in general payments reported to CMS, 2019-2025
23 companies · $1,083 in 2025
The $1,083 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $74.54 · 2023: $697 · 2024: $745 · 2025: $1,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,421 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,420.55 |
| Education | $104.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $368.66 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $287.98 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $200.89 | 2024-2025 | Ingrezza |
| Alkermes, INC. | $198.82 | 2023-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $171.88 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $159.83 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $144.34 | 2023-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.59 | 2023-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $124.10 | 2023-2025 | Trintellix |
| Corium, LLC | $121.60 | 2023-2024 | Azstarys |
| Lundbeck LLC | $98.91 | 2023-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $93.40 | 2025 | Qelbree |
| Tris Pharma INC | $90.79 | 2023-2025 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $61.20 | 2022 | |
| Ironshore Pharmaceuticals INC. | $55.22 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $48.16 | 2023-2024 | Xelstrym |
| Vanda Pharmaceuticals INC. | $47.31 | 2022-2025 | Fanapt |
| Collegium Pharmaceutical, INC. | $42.63 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $40.06 | 2024-2025 | Adzenys Xr-Odt |
| Almatica Pharma LLC | $34.83 | 2024-2025 | Loreev Xr |
| Tms Neurohealth Centers INC. | $30.88 | 2025 | Tms Neurohealth Centers INC. |
| Janssen Biotech, INC. | $28.56 | 2023 | |
| Owp Pharmaceuticals, INC. | $19.94 | 2023 | Subvenite, Lamotrigine |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Treacy Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.